Rapid and sustained response to tocilizumab in patients with polymyalgia rheumatica resistant or intolerant to glucocorticoids: A multicenter open-label study

Journal of Rheumatology

Volumn 43, Issue 1, 2016, Pages 249-250

  Toussirot, Éric ^a,b,c   Martin, Antoine ^d   Soubrier, Martin ^e   Redeker, Serge ^f   Régent, Alexis ^g  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c Hôpital Saint Jacques   (France)

^d Saint Brieuc Hospital   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f Hospital of Abbeville   (France)

^g Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TOCILIZUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; CLINICAL ARTICLE; COMORBIDITY; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; LETTER; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; RHEUMATIC POLYMYALGIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; CLINICAL TRIAL; DRUG RESISTANCE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 85011841618     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150599     Document Type: Letter

References (10)

1. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45.
2. Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-20.
3. Alvarez-Rodríguez L, Lopez-Hoyos M, Mata C, Marin MJ, Calvo-Alen J, Blanco R, et al. Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010;69:263-9.
4. Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res 2012;64:1720-9.
5. Loricera J, Blanco R, Hernández JL, Castañeda S, Mera A, Pérez-Pampín E, et al. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients. Semin Arthritis Rheum 2015;44:717-23.
6. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. Semin Arthritis Rheum 1984;13:322-8.
7. Mori S, Koga Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin Rheumatol 2014 May 8 (E-pub ahead of print).
8. Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R, et al. Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum 2013;43:113-8.
9. Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010;37:1075-6.
10. Al Rashidi A, Hegazi MO, Mohammad SA, Varghese A. Effective control of polymyalgia rheumatica with tocilizumab. J Clin Rheumatol 2013;19:400-1.